Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

View:
Post by Moonshiner592 on Sep 14, 2020 4:26pm

Kalyteran...

https://www.google.ca/amp/s/globalnews.ca/news/7330996/astrazeneca-coronavirus-vaccine-trials-resume/amp/

... think about it .. if the majority of these “vaccine candidates” have significant side effects - and have low efficacy given that they were all developed so fast ... R107 will be in the spotlight if it can boast very little side effects.. and if it can combat COVID better than these trial vaccines??

With millions.. and millions infected around the world... remember we’ve got a world wide patent for R107

Very pivotal... and exciting times ahead for Kaly! 

Comment by JMark80 on Sep 14, 2020 5:18pm
R107 better than vaccines? WTF? Did you even read the article? One woman out of 18,000, which may or may not be related to the vaccine itself. Low efficacy? 91% after one administration, 100% after two.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities